Amgen provides a stable, diversified revenue base of nearly $36.7 billion with significant net income. Iovance Biotherapeutics offers high growth potential through its innovative cell therapies for advanced cancers.
AMGN's biosimilars business is driving growth, with new launches and a deep pipeline helping offset patent losses in key branded drugs.
Regeneron and Amgen have promising weight loss candidates. Both also boast strong lineups that are driving solid revenue growth.
Amgen delivers robust cash flow and high net margins through its established portfolio of blockbuster medications. NovoCure offers a unique direct-to-patient model for tumor treatment, targeting niche oncology markets with tumor-treating electrical fields.
Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
The latest trading day saw Amgen (AMGN) settling at $341.66, representing a -1.78% change from its previous close.
In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
The case, originally filed in 2021 by Harbour Antibodies, asserted that Amgen and Teneobio (an Amgen subsidiary) infringed patents protecting Harbour's groundbreaking antibody discovery platform Delaware jury finds infringement willful and patent valid, and awards full $20.2 million in damages; the findings of willful infringement also entitle the Company to petition the judge to treble the award, potentially increasing the award to up to $60.6 million Harbour BioMed will continue to enforce its broader patent portfolio, with a focus on another patent with substantially greater financial implications—potentially representing up to ten times the damages awarded in this case The verdict represents a complete victory for Harbour BioMed, validating the strength of its proprietary transgenic rodent technology and its commitment to protecting scientific innovation CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 14, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced that a jury in the United States District Court for the District of Delaware has returned a decisive verdict in the Company's favor in the patent infringement lawsuit against Amgen Inc., and Teneobio, Inc. (an Amgen subsidiary) (together, "Amgen").The verdict represents a complete victory for Harbour BioMed, validating the strength of its proprietary transgenic rodent technology and its commitment to protecting scientific innovation.
Eli Lilly, Novo Nordisk, Amgen, Zealand, Structure Therapeutics shared their visions for the future of obesity medicine. Drugmakers pitched doctors and investors on their future drugs at the recent American Diabetes Association (ADA) Scientific Sessions in New Orleans.